<DOC>
	<DOC>NCT00185315</DOC>
	<brief_summary>The aim of this study is to monitor long-term safety and tolerability of iloprost aerosol inhalation therapy in patients suffering from pulmonary hypertension.</brief_summary>
	<brief_title>Safety Follow-up Study of Inhaled Iloprost in Patients With Pulmonary Hypertension</brief_title>
	<detailed_description>This study has previously been posted by Schering AG, Germany. Schering AG has been renamed to Bayer Schering Pharma AG, Germany. Bayer Schering Pharma AG, Germany is the sponsor of the trial.</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hypertension, Pulmonary</mesh_term>
	<mesh_term>Iloprost</mesh_term>
	<criteria>Completion of the 12week treatment period of the predecessor Schering study 97218/300180 Investigator judged iloprost aerosol therapy warranted as a suitable treatment for the respective patient Negative pregnancy test for females Any condition during 12week treatment period of the predecessor Schering study 97218/300180 that prevents participation in the followup safety surveillance study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>71 Years</maximum_age>
	<verification_date>April 2010</verification_date>
</DOC>